Occult neoplastic cells in lymph node sinuses and recurrence/metastasis of stage II/III gastric cancer

Sekido,Yasutomo; Mukai,Masaya; Yamazaki,Masashi; Tajima,Takayuki; Yamamoto,Souichirou; Hasegawa,Sayuri; Kishima,Kyoko; Tajiri,Takuma; Nakamura,Naoya

doi:10.3892/ol.2013.1660

Occult neoplastic cells in lymph node sinuses and recurrence/metastasis of stage II/III gastric cancer

Authors:
- Yasutomo Sekido
- Masaya Mukai
- Masashi Yamazaki
- Takayuki Tajima
- Souichirou Yamamoto
- Sayuri Hasegawa
- Kyoko Kishima
- Takuma Tajiri
- Naoya Nakamura
View Affiliations

Affiliations: Department of Pathology, Tokai University School of Medicine, Bohseidai, Isehara, Kanagawa 259-1193, Japan, Department of Surgery, Tokai University Hachioji Hospital, Hachioji, Tokyo 192-0032, Japan, Department of Pathology, Tokai University Hachioji Hospital, Hachioji, Tokyo 192-0032, Japan
Published online on: November 6, 2013 https://doi.org/10.3892/ol.2013.1660
Pages: 53-58

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In the present study, we investigated the correlation between the presence of occult neoplastic cells (ONCs) in lymph node sinuses and recurrence/metastasis of stage II/III gastric cancer in 164 patients who underwent radical curative resection. We calculated the five-year relapse-free survival rate (5Y-RFS) and five-year overall survival rate (5Y-OS) of the ONC(+) and ONC(-) groups. The 5Y-RFS was 71.4% in the ONC(-) group and 47.5% in the ONC(+) group (P=0.003). The 5Y-OS was 68.8 and 48.4%, respectively (P=0.008). ONCs were found in 34.8% of stage II patients and were also detected in 66.7% of stage III patients. For distinguishing between the recurrence and non-recurrence groups, the sensitivity of ONC(+) was 64.5% (40/62; P=0.003), the positive predictive value (PPV) was 49.4% (40/81), the specificity was 59.8% (61/102) and the negative predictive value (NPV) was 73.5% (61/83). This high sensitivity indicates that ONC positivity may be a significant indicator for high-risk patients in the early postoperative period, and a lack of ONCs may be a useful indicator for identifying low-risk patients, as patients without ONCs had a high NPV.

View Figures

View References

1	Guideline for Gastric Cancer Treatment in Japan. Japanese Gastric Cancer Association; 2nd edition. Tokyo: 2004
2	Guideline for Gastric Cancer Treatment in Japan. Japanese Gastric Cancer Association; 3rd edition. Tokyo: 2010
3	National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1–3, 2000. J Natl Cancer Inst. 93:979–989. 2001.
4	Goldhirsch A, Glick JH, Gelber RD, Coates AS and Senn HJ: Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on adjuvant therapy of primary breast cancer. J Clin Oncol. 19:3817–3827. 2001.
5	Mukai M, Sato S, Komatsu N, Nishida T, Shiba K, Ito I, Nakasaki H and Makuuchi H: Correlation between occult neoplastic cells in the lymph node sinuses and recurrence in patients with curatively resected Dukes’ B colorectal cancer. Oncol Rep. 10:1177–1181. 2003.PubMed/NCBI
6	Mukai M, Sato S, Komatsu N, Nishida T, Shiba K, Ito I, Nakasaki H and Makuuchi H: Correlation between occult neoplastic cells in the lymph node sinuses and recurrence in patients with Dukes’ C colorectal cancer. Oncol Rep. 10:1165–1169. 2003.
7	Mukai M, Sato S, Nakasaki H, Tajima T, Saito Y, Nishiumi N, Iwasaki M, Tokuda Y, Ogoshi K, Inoue H and Makuuchi H: Occult neoplastic cells in the lymph node sinuses and recurrence of primary breast, lung, esophageal, and gastric cancer. Oncol Rep. 11:81–84. 2004.PubMed/NCBI
8	Mukai M, Sato S, Komatsu N, Kimura T, Ninomiya H, Kawada M, Nakasaki H, Ogoshi K and Makuuchi H: Accuracy of criteria for predicting recurrence and metastasis in stage II and III gastric cancer patients with lymph node metastasis. Oncol Rep. 12:63–66. 2004.PubMed/NCBI
9	Mukai M, Sato S, Kimura T, Komatsu N, Ninomiya H, Nakasaki H, Ogoshi K and Makuuchi H: Criteria for predicting the recurrence and metastasis of stage I and II gastric cancer without lymph node metastasis. Oncol Rep. 12:59–62. 2004.PubMed/NCBI
10	Mukai M, Tajima T, Sato S, Ninomiya H, Wakui K, Komatsu N, Tsuchiya K, Nakasaki H and Makuuchi H: Recurrence and 5-FU sensitivity of stage II/III node-positive gastric cancer with occult neoplastic cells in lymph node sinuses. Oncol Rep. 14:1505–1510. 2005.
11	Mukai M, Sato S, Tajima T, Ninomiya H, Wakui K, Komatsu N, Tsuchiya K, Nakasaki H and Makuuchi H: Recurrence and 5-FU sensitivity of stage I/II node-negative breast, lung, or gastric cancer with occult neoplastic cells in lymph node sinuses. Oncol Rep. 15:815–820. 2006.PubMed/NCBI
12	Mukai M, Sato S, Ninomiya H, Wakui K, Komatsu N, Matsui N, Nakamura M, Nakasaki H and Makuuchi H: Sensitivity to CPT-11 and platinum derivatives of stage I/II node-negative breast, lung, and gastric cancer with occult neoplastic cells in lymph node sinuses. Oncol Rep. 18:33–39. 2007.PubMed/NCBI
13	Mukai M, Sato S, Ninomiya H, Wakui K, Komatsu N, Matsui N, Nakamura M, Ogoshi K and Makuuchi H: Sensitivity to CPT-11 and platinum derivatives of stage II/III node-positive gastric cancer with occult neoplastic cells in lymph node sinuses. Ann Cancer Res Ther. 15:22–26. 2007. View Article : Google Scholar : PubMed/NCBI
14	Sekido Y, Mukai M, Kishima K, Tajima T, Hoshikawa T, Nakamura M, Nakamura N and Ogoshi K: Occult neoplastic cells in the lymph node sinuses and recurrence/metastasis of stage II/Dukes’ B colorectal cancer. Oncol Rep. 25:69–73. 2011.PubMed/NCBI
15	Sekido Y, Mukai M, Kishima K, Tajima T, Hoshikawa T, Nakamura M, Nakamura N and Ogoshi K: Occult neoplastic cells in the lymph node sinuses and recurrence/metastasis of stage III/Dukes’ C colorectal cancer. Oncol Rep. 25:915–919. 2011.PubMed/NCBI
16	Sobin L, Gospodarowicz M and Wittekind C: TNM classification of malignant tumors. 7th edition. John Wiley and Sons, Ltd; New York: 2009
17	Nakane PK and Pierce GB Jr: Enzyme-labeled antibodies: preparation and application for localization of antigens. J Histochem Cytochem. 14:929–931. 1966. View Article : Google Scholar : PubMed/NCBI
18	Nakane PK and Pierce GB Jr: Enzyme-labeled antibody for the light and electron microscopic localization of tissue antigens. J Cell Biol. 33:307–318. 1967. View Article : Google Scholar
19	Greenson JK, Isenhart CE, Rice R, Mojzisik C, Houchens D and Martin EW Jr: Identification of occult micrometastases in pericolic lymph nodes of Duke’s B colorectal cancer patients using monoclonal antibodies against cytokeratin and CC49. Correlation with long-term survival. Cancer. 73:563–569. 1994.PubMed/NCBI
20	Nicholson AG, Marks CG and Cook MG: Effect on lymph node status of triple levelling and immunohistochemistry with CAM 5.2 on node negative colorectal carcinomas. Gut. 35:1447–1448. 1994. View Article : Google Scholar
21	Isaka N, Nozue M, Doi M and Fukao K: Prognostic significance of perirectal lymph node micrometastases in Dukes’ B rectal carcinoma: an immunohistochemical study by CAM5.2. Clin Cancer Res. 5:2065–2068. 1999.PubMed/NCBI
22	Prandi M, Lionetto R, Bini A, Francioni G, Accarpio G, Anfossi A, Ballario E, Bacchi G, Bonilauri S, Carobbi A, et al: Prognostic evaluation of stage B colon cancer patients is improved by an adequate lymphadenectomy: results of a secondary analysis of a large scale adjuvant trial. Ann Surg. 235:458–463. 2002. View Article : Google Scholar
23	Mukai M, Ito I, Mukoyama S, Tajima T, Saito Y, Nakasaki H, Sato S and Makuuchi H: Improvement of 10-year survival by Japanese radical lymph node dissection in patients with Dukes’ B and C colorectal cancer: A 17-year retrospective study. Oncol Rep. 10:927–934. 2003.PubMed/NCBI
24	Nelson H, Petrelli N, Carlin A, Couture J, Fleshman J, Guillem J, Miedema B, Ota D and Sargent D: Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst. 93:583–596. 2001. View Article : Google Scholar : PubMed/NCBI
25	JSCCR Guidelines for the Treatment of Colorectal Cancer. Japanese Society for Cancer of the Colon and Rectum (JSCCR); Tokyo: 2009
26	Makuuchi M and Sugihara K: Surgery of the Colon, Rectum and Anus. 2nd edition. Knacks and Pitfalls. Bunkoudou Co, Ltd; Tokyo: 2004
27	Ito I, Mukai M, Ninomiya H, Kishima K, Tsuchiya K, Tajima T, Oida Y, Nakamura M and Makuuchi H: Comparison between intravenous and oral postoperative adjuvant immunochemotherapy in patients with stage II colorectal cancer. Oncol Rep. 20:1189–1194. 2008.
28	Ito I, Mukai M, Ninomiya H, Kishima K, Tsuchiya K, Tajima T, Nakamura M and Makuuchi H: Comparison between intravenous and oral postoperative adjuvant immunochemotherapy in patients with stage III colorectal cancer. Oncol Rep. 20:1521–1526. 2008.
29	Rosai J: Rosai and Ackerman’s Surgical Pathology. 9th edition. Mosby; St. Louis, MO: pp. 670–671. pp. 817–818. 2004
30	Inada K, Shimokawa K, Ikeda T, Hayashi M and Azuma S: Development of liver metastasis in colorectal carcinoma. With special reference to venous invasion and basement membrane laminin. Acta Pathol Jpn. 41:240–245. 1991.
31	Japanese Classification of Gastric Carcinoma. Japanese Gastric Cancer Association; 14th edition. Tokyo, Japan: 2010
32	Muta H, Noguchi M, Kanai Y, Ochiai A, Nawata H and Hirohashi S: E-cadherin gene mutations in signet ring cell carcinoma of the stomach. Jpn J Cancer Res. 87:843–848. 1996. View Article : Google Scholar : PubMed/NCBI
33	Mayer B, Johnson JP, Leitl F, Jauch KW, Heiss MM, Schildberg FW, Birchmeier W and Funke I: E-cadherin expression in primary and metastatic gastric cancer: down-regulation correlates with cellular dedifferentiation and glandular disintegration. Cancer Res. 53:1690–1695. 1993.